seed
Stage
1
Investors
About
Mebias Discovery uses a proprietary membrane protein-NMR platform to identify molecules binding to G-protein coupled receptor (GPCR) targets, aiming to develop novel drugs with improved safety profiles. The company advances its own drug candidates into early clinical development, including Phase 1 trials for a mu-opioid receptor drug and sphingosine 1-phosphate receptor agonists addressing neuropathic pain and neuroinflammation.
Explore Mebias Discovery's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.